Phaseline

Companies › Salubris Biotherapeutics

Salubris Biotherapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Cardiovascular, Oncology; next expected readout Apr 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
JK07
Anti-HER3 antibody fused with EGF-domain of Neuregulin-1b
ERBB3Phase 2Heart Failure With Reduced Ejection Fraction–
JK06
Biparatopic anti-5T4 antibody
TPBGPhase 1Solid TumorApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06369298JK07Phase 2Heart Failure With Reduced Ejection FractionCardiovascularOct 2026
NCT06667960JK06Phase 1Solid TumorOncologyApr 2028

Targets

ERBB3 (1) TPBG (1)

Companies with the same targets

Shanghai Institute Of Biological Products Hummingbird Bioscience Daiichi Sankyo Merck & Co. (MSD) Partner Therapeutics NeoTX Therapeutics Qilu Pharmaceutical

Companies built like this

Aston Sci. Chengdu SciMount Pharmatech SystImmune Beijing Sungen Biomedical Technology MediWound

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.